Patients with cancer-associated thrombosis (CAT) are at high risk of recurrent venous
thromboembolism (VTE) and major bleeding complications. Risks vary significantly between …

Anticoagulant treatment in patients with primary and metastatic brain cancer is a concern
due to risk of intracranial hemorrhage (ICH). We performed a systematic review and meta …

Background There are no data on the effect of low‐dose anticoagulation as secondary
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …

Cancer‐associated venous thromboembolism (VTE) is a leading cause of morbidity and
mortality in patients with cancer. Treatment of cancer‐associated VTE comes with a …

Introduction Patients with central nervous system malignancies have limited representation
in studies evaluating DOACs for VTE treatment. This study evaluated the safety and efficacy …

Background The safety and efficacy of direct-acting oral anticoagulants (DOACs) for
therapeutic anticoagulation in the setting of primary or metastatic brain cancer is not known …

Cancer patients have varying incidence, depth and duration of thrombocytopenia. The
mainstay of managing severe chemotherapy-induced thrombocytopenia (CIT) in cancer is …

Patients with cancer are at a high risk of symptomatic venous thromboembolism (VTE),
which is a common cause of morbidity and mortality in this patient population. Increased risk …

Venous thromboembolism (VTE) is a common complication in patients with cancer. The risk
of emergent VTE is four-to seven-fold higher in cancer patients compared to non-cancer …

The incidence of oral cancer is still increasing. It has become very common in patients with
malignant tumors, which has forced medical personnel to continuously explore its treatment …